HEC169096

Phase I: Primary purpose: to determine the maximum tolerated dose (MTD)/phase II recommended dose (RP2D) of HEC169096; Secondary purpose: to evaluate the safety and tolerability of HEC169096 in subjects with advanced solid tumors; Observe the PK characteristics and drug metabolism conversion of HEC169096 in subjects with advanced solid tumors; Evaluate the efficacy of HEC169096 in subjects with advanced solid tumors; Phase II: Primary purpose: to evaluate the ORR of HEC169096 in subjects with RET fusion NSCLC, RET mutation MTC and other RET-altered advanced solid tumors; Secondary purpose: to evaluate other anti-tumor efficacy indicators (DCR, DOR, CNS ORR, CNS DOR, CBR, PFS, OS); Evaluate the safety and tolerability of HEC169096 in subjects with RET fusion NSCLC, RET mutation MTC and other RET-altered advanced solid tumors; Observe the PK characteristics and drug metabolism conversion of HEC169096 in subjects with RET fusion NSCLC, RET mutation MTC and other RET-altered advanced solid tumors.